Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of HRS-5765 in Healthy Participants
Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Summary
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.
Official title: A Randomized, Double-Blind, Dose-Escalation, Placebo-Parallel Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HRS-5765 in Healthy Subjects, as Well as the Effect of Food on the Pharmacokinetics of HRS-5765 and the Effect of HRS-5765 on CYP3A4 Metabolic Enzymes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2026-04
Completion Date
2027-01
Last Updated
2026-04-24
Healthy Volunteers
Yes
Conditions
Interventions
HRS-5765 Tablet
HRS-5765 tablet, specified dose on specified day.
HRS-5765 Tablet Placebo
HRS-5765 tablet placebo, specified dose on specified day.
Locations (1)
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China